# Does Semaglutide Improve Depressive Symptoms in Patients With Major Depressive Disorder and Overweight or Obesity

> **NCT07136714** · PHASE4 · RECRUITING · sponsor: **Nordsjaellands Hospital** · enrollment: 116 (estimated)

## Conditions studied

- Major Depressive Disorder

## Interventions

- **DRUG:** Semaglutide Injectable Product
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07136714
- **Lead sponsor:** Nordsjaellands Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-11
- **Primary completion:** 2027-09
- **Final completion:** 2027-09
- **Target enrollment:** 116 (ESTIMATED)
- **Last updated:** 2026-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07136714

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07136714, "Does Semaglutide Improve Depressive Symptoms in Patients With Major Depressive Disorder and Overweight or Obesity". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT07136714. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*